Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase.

MLA

Fiorillo, Marco, et al. “Bedaquiline, an FDA-Approved Drug, Inhibits Mitochondrial ATP Production and Metastasis in Vivo, by Targeting the Gamma Subunit (ATP5F1C) of the ATP Synthase.” Cell Death and Differentiation, vol. 28, no. 9, Sept. 2021, pp. 2797–817. EBSCOhost, https://doi.org/10.1038/s41418-021-00788-x.

APA

Fiorillo, M., Scatena, C., Naccarato, A. G., Sotgia, F., & Lisanti, M. P. (2021). Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell Death and Differentiation, 28(9), 2797–2817. https://doi.org/10.1038/s41418-021-00788-x

Chicago

Fiorillo, Marco, Cristian Scatena, Antonio Giuseppe Naccarato, Federica Sotgia, and Michael P Lisanti. 2021. “Bedaquiline, an FDA-Approved Drug, Inhibits Mitochondrial ATP Production and Metastasis in Vivo, by Targeting the Gamma Subunit (ATP5F1C) of the ATP Synthase.” Cell Death and Differentiation 28 (9): 2797–2817. doi:10.1038/s41418-021-00788-x.